COVID-19 Update

We understand that you may be concerned about how the evolving COVID-19 situation could impact access to your medicine.

Alexion’s goal is to always manage a robust supply chain that delivers medicines that are secure, sterile and meet our rigorous quality standards. In addition, due to the seriousness of the diseases we treat, we strive to maintain sufficient inventory levels to ensure their supply to the patients who rely on them. We have taken proactive measures to mitigate the risk of potential interruptions in supply, and we are continuing to actively monitor this dynamic and rapidly evolving situation worldwide.

Hypophosphatasia (HPP) is a genetic, metabolic disorder. Patients with HPP, especially infants and children with perinatal-infantile HPP, may have underlying respiratory/breathing problems.1 Therefore, having HPP may increase the risk of having a severe illness from COVID-19.2,3 To minimize exposure, handwashing and daily cleaning of frequently touched surfaces (including wheelchairs) are recommended measures to prevent illness.3,4

Strensiq® (asfotase alfa) is a type of medication known as an enzyme replacement therapy.5 Strensiq works in patients with hypophosphatasia (HPP) by replacing the deficient enzyme, known as alkaline phosphatase, which allows the body to build or mineralize bones. Strensiq works differently than medications known as immunosuppressants.5,6 Across the clinical trials for Strensiq, patients receiving Strensiq did not show a reduced immune system.3 Based on the way Strensiq works and safety data compiled, it does not appear that patients treated with Strensiq have a higher risk of developing a viral infection.5-7

Contact your doctor if you have any questions or concerns about treatment with Strensiq during the COVID-19 pandemic, particularly if you are considering missing or delaying an existing treatment because of COVID-19.

Alexion will continue to support community activities during this time. While externally organized events are being cancelled or postponed, we will continue to work with patient advocacy organizations to review requests and support programs when possible.

Alexion is hosting virtual education events about disease and treatment. Contact OneSource™ for more information at 1.888.765.4747.

Moving forward,

  • Continue to follow your physician’s advice about your specific medical situation
  • Follow directions provided by your local government

For more information on the evolving COVID-19 pandemic, please monitor public health authority websites, such as www.cdc.gov or www.who.int.

  1. Whyte MP, Leung E, Wilcox WR, Liese J, Argente J, Martos-Moreno GA, on behalf of the Study 011-10 Investigators. Natural History of Perinatal and Infantile Hypophosphatasia: A Retrospective Study. J Pediatr. 2019;209:116-124.
  2. Centers for Disease Control and Prevention. People who are at higher risk for severe illness. https://www.cdc.gov/coronavirus/2019-ncov/specific-groups/people-at-higher-risk.html. Accessed March 27, 2020.
  3. European Centre for Disease Prevention and Control. Q&A on COVID-19. https://www.ecdc.europa.eu/en/novel-coronavirus-china/questions-answers. Accessed March 30, 2020.
  4. https://www.cdc.gov/coronavirus/2019-ncov/prepare/prevention.html. Accessed March 24, 2020.
  5. Strensiq® (asfotase alfa) US Full Prescribing Information. Alexion Pharmaceuticals, Inc.
  6. Carbone J, Del Pozo N, Gallego A, Sarmiento E. Immunological risk factors for infection after immunosuppressive and biologic therapies. Expert Rev Anti Infect Ther. 2011;9(4):405-413. doi:10.1586/eri.10.178.
  7. Data on file. Integrated Safety Summary (ISS). Alexion Pharmaceuticals, Inc.

US/STQ-H/0075

× +
IMPORTANT SAFETY INFORMATION & INDICATION

STRENSIQ may cause serious side effects, including

  • Serious allergic (hypersensitivity) reactions happened in some people who use STRENSIQ. Stop using STRENSIQ and go to the nearest hospital emergency room right away if you or your loved one have any of the signs and symptoms of a serious allergic reaction, including
    • Difficulty breathing
    • Swelling of your eyes, lips, or tongue
    • Hives
    • Feeling faint
    • Nausea or vomiting
    • Dizziness
    • Itching of your lips, tongue, or throat
    • Choking sensation
  • Skin thickening or pits at the injection site (lipodystrophy) has happened several months after using STRENSIQ.
  • Calcium buildup in the eyes and kidneys can occur if you or your loved one have HPP. Your healthcare provider should check the eyes and kidneys while you or your loved one use STRENSIQ.
  • Decreased efficacy. Contact your healthcare provider if you or your loved one notice STRENSIQ is no longer working or experience worsening symptoms of HPP (e.g., increased respiratory support, increased difficulty walking, new fractures).

The most common side effects of STRENSIQ include local skin injection-site reactions (red skin patches, bruising, color change, pain, itching, thinning, swelling, pits, and bumps) and calcium buildup in your eyes and kidneys.

Strensiq may affect other lab test results, therefore it is important that you present your Medical Alert Card to your healthcare team so they are aware that you are being treated with an alkaline phosphatase (ALP) replacement therapy which may cause incorrect results on certain laboratory tests.

Tell your doctor if you are pregnant or plan to become pregnant or are breastfeeding or plan to breastfeed.

These are not all the possible side effects of STRENSIQ. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1‑800‑FDA‑1088.

INDICATION
What is STRENSIQ?
Strensiq is a prescription medicine used to treat people with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).

Please see STRENSIQ full Prescribing Information, including Patient Information and Instructions for Use.
IMPORTANT SAFETY INFORMATION & INDICATION

STRENSIQ may cause serious side effects, including

  • Serious allergic (hypersensitivity) reactions happened in some people who use STRENSIQ. Stop using STRENSIQ and go to the nearest hospital emergency room right away if you or your loved one have any of the signs and symptoms of a serious allergic reaction, including
    • Difficulty breathing
    • Swelling of your eyes, lips, or tongue
    • Hives
    • Feeling faint
    • Nausea or vomiting
    • Dizziness
    • Itching of your lips, tongue, or throat
    • Choking sensation
  • Skin thickening or pits at the injection site (lipodystrophy) has happened several months after using STRENSIQ.
  • Calcium buildup in the eyes and kidneys can occur if you or your loved one have HPP. Your healthcare provider should check the eyes and kidneys while you or your loved one use STRENSIQ.
  • Decreased efficacy. Contact your healthcare provider if you or your loved one notice STRENSIQ is no longer working or experience worsening symptoms of HPP (e.g., increased respiratory support, increased difficulty walking, new fractures).

The most common side effects of STRENSIQ include local skin injection-site reactions (red skin patches, bruising, color change, pain, itching, thinning, swelling, pits, and bumps) and calcium buildup in your eyes and kidneys.

Strensiq may affect other lab test results, therefore it is important that you present your Medical Alert Card to your healthcare team so they are aware that you are being treated with an alkaline phosphatase (ALP) replacement therapy which may cause incorrect results on certain laboratory tests.

Tell your doctor if you are pregnant or plan to become pregnant or are breastfeeding or plan to breastfeed.

These are not all the possible side effects of STRENSIQ. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1‑800‑FDA‑1088.

INDICATION
What is STRENSIQ?
Strensiq is a prescription medicine used to treat people with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).

Please see STRENSIQ full Prescribing Information, including Patient Information and Instructions for Use.